Gepatit B e-antigeniga qarshi antitanachalar (anti-HBe)
Kod:17014|CPT:86707|LOINC:13953-5
| Kabi | Anti-HBe (Gepatit B e-antigeniga qarshi antitanachalar) |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Kimyoluminessent immunoanaliz (CLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Do not smoke for 30 minutes before the blood draw.
Qanday foydalanish
Gepatit B e-antigeniga qarshi antitanachalar testi (anti-HBe, HBeAb) HBV serologiyasi va klinik ma'lumotlar bilan birga gepatit B infeksiyasining fazasini aniqlash va prognozni baholash uchun qo'llaniladi. U HBeAg ijobiyligidan anti-HBe ijobiyligiga serokonversiyani hujjatlashtiradi, klinik kechishni kuzatishga yordam beradi va klinik boshqaruv qarorlarini qo'llab-quvvatlash maqsadida antivirus (antiviral) terapiyaga virologik javobni baholashga yordam beradi.
Cheklovlar
Gepatit B virusi (HBV) qon va tana suyuqliklari orqali yuqadigan DNK virusi bo'lib, o'tkir kasallik chaqirishi yoki sirroz va gepatosellyulyar karsinoma xavfi bilan surunkali infeksiyaga o'tishi mumkin. Asosiy serologik markerlar qatoriga HBsAg (envelope antigen), HBcAg va yadro bilan bog'liq HBeAg kiradi; HBeAg ning mavjudligi faol virus replikatsiyasi va yuqtiruvchanlikning oshganini bildiradi. Anti-HBe odatda infeksiyadan 8–16 hafta o'tgach, HBeAg yo'qolganda paydo bo'ladi va o'tkir fazaning yakunlanishini yoki kamroq replikativ holatga o'tishni bildiradi. HBeAg-musbat surunkali gepatit B bo'lgan bemorlarda HBeAg dan anti-HBe ga serokonversiya terapiyaga virologik javob bilan korrelyatsiyalanadi. Orqaga serokonversiya (oldingi anti-HBe dan so'ng HBeAg ning qayta paydo bo'lishi) immunosupressiya sharoitida virus reaktivatsiyasi bilan kuzatilishi mumkin. Anti-HBe besh yilgacha saqlanib turishi mumkin va odatda anti-HBs va anti-HBc rivojlanishidan avval susayadi. Talqin qilishda boshqa HBV markerlari va HBV DNK tekshiruvi bilan integratsiya zarur, chunki precore/core promoter mutantlari anti-HBe ijobiy bo'lishiga qaramay yuqtiruvchanlikni saqlab qolishi mumkin; ilg'or sirrozda serokonversiya prognozning yaxshilanishini har doim ham anglatmaydi.
| O'lchov birligi | qualitative | ||||
|---|---|---|---|---|---|
| Referens oraliq |
| ||||
| Ko'rsatmalar | Evaluation after confirmation of hepatitis B surface antigen (HBsAg) positivity, Ongoing monitoring of hepatitis B virus infection activity, Baseline, on-therapy, and post-therapy assessments during HBV treatment |
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 0.5 mL (min 0.2 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167(11):794-804. PubMed 29159414
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1-31. PubMed 29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560-1599. PubMed 29405329
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015;64(RR-03):1-137. PubMed 26042815
Vozianova ZI. Infectious and Parasitic Diseases: In 3 volumes. Kyiv: Zdorov'ye; 2000. Vol 1:601–636.
Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005:1822-1855.